Form 4: Centene CEO Sarah London Boosts Stake with New Equity Awards

Centene CEO Sarah London reported the acquisition of over 520,000 shares of common stock through equity awards, increasing her beneficial ownership.

Summary

• Sarah London, CEO and Director of Centene Corp (CNC), acquired 520,720 shares of common stock on January 26, 2026, at a price of $0 per share.
• Following this transaction, her total beneficial ownership of common stock increased to 1,365,995 shares.
• The acquired shares include 138,859 restricted stock units (RSUs) that will vest in three annual installments beginning on March 15, 2027.
• An additional 69,429 restricted stock units (RSUs) are included, which will vest in five annual installments beginning on March 15, 2027.
• The award further comprises 312,432 performance stock units (PSUs) reported at target level performance, with actual vesting on March 15, 2029, ranging from 0% to 200% of target.
• The actual number of PSUs vesting is contingent on Centene's stock price performance for the final 20 trading days of 2025 compared to the final 60 trading days of 2028.
• London also beneficially owns 13,449 common stock options with an exercise price of $81.85, granted on December 15, 2021, and expiring on December 15, 2031.
• These options may become exercisable on or after the third anniversary of the grant date if Centene's common stock closing price equals or exceeds $100 per share for 20 consecutive trading days following the grant date.

Sentiment

Score: 7

Explanation: The filing reports an increase in the CEO's beneficial ownership through equity awards, which generally signals strong alignment with shareholder interests and confidence in future performance. The performance-based components further reinforce this positive alignment.

Positives

• CEO Sarah London's increased beneficial ownership through equity awards aligns her interests more closely with shareholders.
• The inclusion of performance stock units incentivizes long-term stock price performance and value creation for the company.
• The structured vesting schedules for both restricted stock units and performance stock units serve as a retention mechanism for key management.

Risks

• The actual number of performance stock units that will vest is variable and dependent on the company's stock price performance, introducing uncertainty in the ultimate value of this compensation component.
• The exercisability of the stock options is contingent on Centene's stock price reaching a specific threshold ($100) for a sustained period, meaning the options may not become exercisable if market conditions are not met.

Future Outlook

The vesting of performance stock units on March 15, 2029, is directly tied to Centene's stock price performance between late 2025 and late 2028, indicating a clear future focus on increasing shareholder value. Additionally, the stock options incentivize reaching a $100 stock price target for exercisability.

Industry Context

This filing reflects standard executive compensation practices within the healthcare managed care industry, where equity awards such as Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) are commonly utilized to align executive incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The use of RSUs and PSUs as a significant component of executive compensation is a common practice among large-cap healthcare companies, similar to peers like UnitedHealth Group (UNH) or Elevance Health (ELV).
• The specified vesting schedules (3-year, 5-year, and performance-based) are typical for retaining executives and incentivizing sustained performance, aligning with established corporate governance best practices for executive compensation.
• The performance criteria for PSUs, based on stock price performance, is a standard metric, although some industry peers may also incorporate operational or environmental, social, and governance (ESG) metrics.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholders due to significant equity awards tied to company performance.
• Management: The CEO's compensation structure is reinforced with long-term incentives, encouraging sustained focus on company growth and stock performance.

Next Steps

• Vesting of 138,859 restricted stock units in three annual installments beginning March 15, 2027.
• Vesting of 69,429 restricted stock units in five annual installments beginning March 15, 2027.
• Vesting of performance stock units on March 15, 2029, contingent on stock price performance.
• Potential exercisability of stock options after December 15, 2024, if specific stock price conditions are met.

Key Dates

Recommendation

This Form 4 reports an executive compensation event, specifically the grant of equity awards to the CEO. While the increased alignment of the CEO's interests with shareholders through performance-based incentives is generally positive, this filing alone does not provide sufficient information on the company's operational or financial performance to warrant a 'buy' or 'sell' recommendation. It is a routine disclosure of executive compensation, which typically supports a 'hold' stance unless other significant company news or financial results are considered.

Keywords

Centene Corp, CNC, Sarah London, Insider Transaction, Form 4, Equity Award, Restricted Stock Units, Performance Stock Units, Stock Options, CEO Compensation, Beneficial Ownership